NasdaqGS:MBXPharmaceuticals
A Look at MBX Biosciences (MBX) Valuation After Goldman Sachs’ Bearish Initiation of Coverage
MBX Biosciences (MBX) slipped onto more traders radars after Goldman Sachs launched coverage with a bearish stance, questioning how much value the company can prove beyond its lead hormone therapy canvuparatide.
See our latest analysis for MBX Biosciences.
Despite Goldman’s cautious view, MBX’s recent 1 day share price return of 3.5 percent to 28.67 dollars comes after a powerful 90 day share price return of 186.7 percent and 1 year total shareholder return of 40.8 percent, suggesting...